Assess your knowledge of escalation beyond JAK inhibition in cGVHD. Explore inflammatory vs fibrotic mechanisms, 2L+ clinical trial outcomes, and emerging real-world insights in third-line management.
6 questions
Correct Answer: C
Progressive sclerosis, new organ involvement, or worsening pulmonary function after JAK inhibition reflects inadequate disease control and supports escalation. Stable or improving disease does not meet criteria for treatment failure.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12139230/pdf/main.pdf https://www.mdpi.com/2073-4409/13/18/1524 Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease - PubMed
Correct Answer: A
Late-phase (fibrotic) cGVHD is characterized by macrophage polarization and secretion of profibrotic cytokines such as TGF-β and PDGF, driving fibroblast activation and sclerosis.
Correct Answer: D
CSF-1 receptor signaling regulates monocyte differentiation into activated macrophages. Inhibition of this pathway reduces profibrotic cytokine secretion implicated in sclerotic, treatment-refractory disease.
Correct Answer: B
Objective response rate (ORR), including partial and complete responses by NIH criteria, is a standard primary endpoint in 2L+ cGVHD trials, often accompanied by failure-free survival and steroid taper outcomes.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12139230/pdf/main.pdfhttps://www.mdpi.com/2073-4409/13/18/1524Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease - PubMed
Real-world 3L populations typically include patients with advanced, multi-organ disease who have failed ≥2 prior systemic therapies, including JAK inhibition.
Real-world combination experiences in refractory cGVHD have demonstrated ORRs in the ~60% range with acceptable safety, supporting feasibility in select highly refractory patients.